News | September 19, 2013

Corindus Launches Study of Robotic Angioplasty Effectiveness and Safety

PRECISION Registry will collect data from sites nationwide to study use of CorPath in routine clinical practice

Corindus CorPath 200 RECISION Registry Clinical Trial

September 19, 2013 – Corindus Vascular Robotics announced the PRECISION Registry, an ongoing clinical study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices. Giora Weisz, associate professor of Medicine at Columbia University Medical Center, will lead the study.

“Although manual PCI procedures are a widely accepted practice, I believe there is an opportunity for improvements to be made in stent size selection and precision movements that can only be offered with robotic assistance,” said Weisz. “We have seen initial clinical indications linked to the benefits of robotics during the CorPath PRECISE clinical trial, published recently, and with the launch of the PRECISION Registry, we expect to see continued trending towards improved clinical output resulting from the routine practice of robotics during PCIs.”

Corindus’ CorPath 200 System is the first and only U.S. Food and Drug Administration (FDA)-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.  

As a result of the increasing interest in the CorPath System, Corindus Vascular Robotics has grown its patent portfolio to now include more than 30 issued patents worldwide. Additionally, following FDA clearance in July 2012, Corindus has increased its workforce, including an expansion of its sales team, and has recently relocated its office to a larger facility in Waltham, Mass.

For more information: www.corindus.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init